FDA grants priority review for asfotase alfa as treatment for hypophosphatasia
Alexion announced the FDA has accepted for Priority Review the Company's BLA for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for treatment of patients with infantile- and juvenile-onset hypophosphatasia. March 02, 2015